Exact Sciences Stock - Analyst consensus and background on the cancer-testing specialist

Exact Sciences stock remains shaped by expectations for its cancer diagnostics franchise. On a quiet news Sunday, the focus shifts to what analysts expect for the Nasdaq-listed company and how its core tests drive the business.

Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 20:17 UTC. Details in the imprint.

Exact Sciences (US30063P1057) is a US-based cancer diagnostics company listed on Nasdaq. With no fresh corporate headlines on Sunday, the focus turns to analyst expectations and the company’s positioning in the fast-growing cancer-testing market.

What analysts currently expect

Recent consensus data compiled by several financial portals show that most analysts remain constructive on Exact Sciences, although target prices and ratings vary by bank and time horizon. Overall, the company is still treated as a growth name in diagnostics.

Across major houses, the stock typically carries a mix of Buy and Hold ratings, reflecting both optimism about long-term cancer-screening demand and caution about valuation and competition. Price targets cluster well above the recent share price, but dispersion is meaningful.

How the company is positioned

Exact Sciences describes itself as a precision oncology company focused on cancer screening and diagnostic tests, including well-known stool-based tests for colorectal cancer. Management emphasizes a long-term goal of expanding into earlier detection across multiple tumor types.

The growth strategy combines expanding test adoption in the US, adding new indications, and pushing into international markets where reimbursement and awareness can lag the US by several years. Against this backdrop, analyst models typically assume continued double-digit revenue growth over the medium term.

What the company sells

Exact Sciences generates most of its revenue from cancer screening and diagnostic tests performed in its laboratories, particularly noninvasive colorectal cancer screening and related assays. The company also offers precision oncology tests that analyze tumor biomarkers to help guide treatment decisions.

Where the stock trades today

The shares of Exact Sciences (US30063P1057) trade on Nasdaq in US dollars; a reliable, up-to-date quote with exact price and timestamp could not be independently verified at the time of this editorial review.

Key facts on Exact Sciences stock

• Company: Exact Sciences Corp.
• ISIN: US30063P1057
• Venue: Nasdaq
• Sector / Industry: Health Care - Diagnostics & Research

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.